Skip to main content

Drug Safety Update

From:
Medicines and Healthcare products Regulatory Agency
Skip to results
  • Letters and drug alerts sent to healthcare professionals in July 2018

    Letters were sent about valproate medicines, atezolizumab (Tecentriq▼), and nusinersen (Spinraza▼). MHRA issued alerts and recalls for valsartan-containing medicines, Fiasp FlexTouch pre-filled pens, melatonin capsules, and …

    • Therapeutic area: Cancer and 12 others
    • Published:
  • Letters sent to healthcare professionals in June 2018

    Letters were sent about Cetrotide (cetrorelix acetate), Eperzan▼(albiglutide), darunavir/cobicistat, Keytruda▼ (pembrolizumab), Denzapine (clozapine) 50 mg/mL oral suspension, and Bleo-Kyowa (bleomycin sulphate).

    • Therapeutic area: Anaesthesia and intensive care and 9 others
    • Published:
  • Recombinant human erythropoietins: treating anaemia in cancer

    Patients with cancer who received recombinant human erythropoietins in clinical trials had an increased risk of tumour progression and reduced overall survival compared with study controls.

    • Therapeutic area: Cancer
    • Published:
  • Letters and medicine recalls sent to healthcare professionals in August 2023

    A summary of recent letters and notifications sent to healthcare professionals about medicines, and a recent National Patient Safety Alert highlighting the risk of deaths and serious injuries from entrapment or falls relatin…

    • Therapeutic area: Cancer and 9 others
    • Published: